Applications of Tert-Butyl Sarcosinate Hydrochloride in Industrial Manufacturing

Tert-Butyl Sarcosinate Hydrochloride delivers functional value in specific high-performance applications where its unique chemical structure meets demanding industrial requirements. Drawing from manufacturing experience and direct collaboration with downstream producers, we summarize its primary real-world uses below, along with critical formulation, compliance, and process integration details.

1. Chiral Auxiliary for Asymmetric Organic Synthesis

In pharmaceutical and fine chemical industries, Tert-Butyl Sarcosinate Hydrochloride plays a critical role as a chiral auxiliary for enantioselective synthesis. Process chemists incorporate this compound to control stereochemistry in the preparation of optically active intermediates for APIs and advanced intermediates. Its use aligns with scale-up demands from kilogram to multi-ton production, supporting batch and continuous flow operations.

Industry compliance standards

• ICH Q7 Good Manufacturing Practices for Active Pharmaceutical Ingredients
• USP General Chapter <1078> Good Manufacturing Practices for Bulk Pharmaceutical Excipients
• EU GMP Part II
• REACH Annex XIII criteria for intermediates

Typical usage ratio

• Usage levels range from 0.2 to 0.7 molar equivalents relative to the starting substrate. Chemists determine the exact ratio for each transformation to balance enantioselectivity and process economy.

Downstream process integration

• Operators add the material after the initial substrate dissolution during chiral induction steps. Post-reaction, they separate and recover the auxiliary or its derivatives prior to downstream derivatization or purification.

Final product types

• Chiral pharmaceutical intermediates
• Enantioenriched specialty amines
• Non-racemic α-amino acid derivatives
• Building blocks for peptide-based APIs

2. Intermediate for Modified Amino Acid Synthesis

Peptide and oligonucleotide manufacturers utilize Tert-Butyl Sarcosinate Hydrochloride as a protected glycine-type building block, essential for preparing sterically regulated modified amino acids. Its tert-butyl group confers acid-labile protection, supporting solid-phase and solution-phase peptide synthesis, while the hydrochloride salt improves solubility and handling.

Industry compliance standards

• US FDA 21 CFR Part 211 Current Good Manufacturing Practice for Finished Pharmaceuticals
• EU EudraLex Volume 4 GMP Guidelines
• Japanese Pharmacopoeia General Notices for amino acid derivatives
• ISO 9001:2015 Quality Management System

Typical usage ratio

• Standard protocols employ 1.05–1.2 equivalents, relative to the coupling partners, to ensure full conversion in amidation or esterification steps. The ratio can adjust slightly during scale-up for cost control.

Downstream process integration

• Technical operators introduce the compound at the protected amino acid assembly phase, leveraging carbodiimide or mixed anhydride strategies. They maintain a controlled pH and temperature profile to sustain reactivity and prevent side reactions.

Final product types

• Protected N-methylglycine derivatives
• Custom-modified peptide sequences
• Research peptides containing sarcosine moieties
• Synthetic intermediates for peptide-based diagnostic kits

3. Precursor in Specialty Surfactant Production

Manufacturers of specialty surfactants in personal care and textile auxiliaries convert Tert-Butyl Sarcosinate Hydrochloride through targeted N-alkylation and transesterification, exploiting its mild detergent properties and compatibility with nonionic and amphoteric systems. Downstream applications demand strictly controlled impurity profiles and mild processing conditions to minimize byproduct formation and ensure user safety.

Industry compliance standards

• OECD Guidelines for the Testing of Chemicals (Biodegradability and Ecotoxicity)
• ISO 14001:2015 Environmental Management Systems
• Regulation (EC) No 648/2004 on Detergents
• Cosmetics Regulation (EC) No 1223/2009 for personal care applications

Typical usage ratio

• Typical addition varies between 5% and 15% by weight in intermediate formulations, depending on chain length of the alkylating agent and target surface-active profile.

Downstream process integration

• Operators dose the material post-hydrolysis and prior to final alkylation, ensuring full conversion. Quality control teams monitor both reaction yield and unwanted amine or ester residuals at this stage.

Final product types

• Mild amphoteric surfactants for shampoos and facial cleansers
• Wetting agents for textile scouring baths
• Auxiliary components in liquid detergents
• Performance additives in low-foaming rinse aids

4. Intermediate for API Synthesis: N-Methylated Amino Compound Pathways

Pharmaceutical manufacturing routes for active ingredients and related compounds demand N-methylated amino acid precursors with high purity and consistent stereochemical integrity. Production teams rely on Tert-Butyl Sarcosinate Hydrochloride as a scalable intermediate for these advanced synthetic pathways, especially where competitive processes require reduced side product formation and improved downstream yield.

Industry compliance standards

• International Conference on Harmonisation (ICH) Q3A/B guidelines for impurity control
• Pharmacopeial monographs for amino acid derivatives (USP/NF, Ph. Eur.)
• US FDA DMF (Drug Master File) registration for intermediates
• WHO Good Manufacturing Practices for pharmaceutical products

Typical usage ratio

• Depending on the API pathway, usage ranges between 0.9 and 1.4 equivalents relative to the coupling or methylation partner, calculated for stoichiometric completion with minimal waste.

Downstream process integration

• Technicians introduce the material after base substrate purification, using controlled addition under inert atmosphere due to moisture sensitivity until protection group removal and further derivatization.

Final product types

• N-methylated amino acid building blocks for APIs (e.g., sarcosine derivatives)
• Pharmaceutical intermediates for central nervous system agents
• Advanced precursors for antitumor or antibiotic candidates
• Protected amino acid segments for peptide analog synthesis